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Abstract: Langerhans cells (LCs) have been scrutinized many
times in studies of the pathogenesis of graft-versus-host disease
(GVHD). As migratory dendritic cells, LCs are capable of direct
antigen presentation to cytotoxic T cells. Their self-renewal
capacity has led to speculation that persistent recipient LCs could
provide a continuous source of host antigen to donor T cells
infused during hematopoietic stem cell transplantation (HSCT).
In this issue of Experimental Dermatology, a new study examines
at the relationship between recipient LCs and chronic GVHD.
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The role of Langerhans cells (LCs) in the pathogenesis of graft-
versus-host disease (GVHD) remains enigmatic. LCs are the para-
digmatic migratory dendritic cell (DC) and are potent at priming
CD8+ T cells (1). In haematopoietic stem cell transplantation
(HSCT), the potential of recipient LCs to promote GVHD by pre-
senting host antigen to donor cytotoxic T cells was first proposed
more than 30 years ago by Claude Perreault (2). More recent
enquiry has been galvanized by two important observations: first,
that deletion of recipient antigen-presenting cell function can
ablate GVHD in mice (3), and second, that LCs proliferate locally
and maintain homeostasis independently of the bone marrow,
even after myeloablative transplantation (4,5).
Human studies had previously shown that LCs were in cell
cycle (6) and understanding the turnover of LCs, especially after
reduced intensity transplantation, became a pivotal question. Sev-
eral studies asked whether persistent recipient LCs were associ-
ated with an increased risk of acute GVHD and might therefore
offer a new target of therapeutic intervention (7,8). However, a
key factor was overlooked, namely that acute GVHD itself may
cause sufficient cutaneous inflammation to deliver a knockout
blow to resident LCs, resulting in the recruitment of donor-
derived cells (5). This presented a paradox: the very ‘risk factor’
for GVHD, a high proportion of persistent recipient LCs, is more
likely to be observed in the absence of GVHD. Another way to
consider this is that recipient LCs, although self-renewing, are
actually self-limiting in terms of priming donor T cells: the more
inflammation that results, the more likely they are to disappear
(Fig. 1).
A recent paper in Experimental Dermatology examines a new
aspect, the relationship between persistent recipient LCs and the
occurrence of chronic GVHD (9). Perhaps mindful of the caveat
just described, attention was focused on a defined subset of
patients who had not experienced acute GVHD. In this way, a
specific question could be asked whether more recipient LCs at
day 100 predicted a greater risk of subsequent chronic GVHD.
Twenty-two patients were free of GVHD at day 100, but the 6/22
patients who developed chronic GVHD had a similar level of reci-
pient LC to those who did not (59%; range 22–95%).
The surprising finding is not the lack of an association with
chronic GVHD, which is postulated to depend more on indirect
antigen presentation by donor-derived DCs (10–12), but the high
level of persistent recipient LCs reported. Although a lack of acute
GVHD would favour retention of recipient LCs, previous reports
had indicated that recipient LCs were largely eliminated by day
100 post-transplant (2,7,8). Andani and colleagues highlight a
technical difference between their in situ analysis and studies
showing high donor chimerism in LCs isolated from epidermal
sheets by migration (7,8). Migration is an excellent way to isolate
up to 1000 LCs from a small skin biopsy and to distinguish them
from contaminating keratinocytes. A criticism of this approach is
Figure 1. Association of GVHD with donor LC engraftment. LCs are self-renewing
in the steady state. Conditioning with chemo/radiotherapy for HSCT leads to
transient depletion and repopulation, probably by local proliferation. Inflammation
caused by acute GVHD leads to loss of recipient LCs and engraftment of donor
cells (also self-renewing). This means that a biopsy taken after acute GVHD is likely
to find an inverse association between the persistence of recipient LCs and acute
GVHD. Owing to the fact that acute GVHD is the most significant risk factor for
chronic GVHD, high donor LC engraftment at 100 days is also more likely to be
associated with chronic GVHD, although this has not been tested. Conversely,
patients without acute GVHD are more likely to retain recipient LCs. Whether the
level of recipient LCs remaining predicts the incidence of chronic GVHD is the
question posed by Adani and colleagues in Experimental Dermatology. *Other
reports suggest 90% engraftment may occur even in the absence of GVHD.
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that in vitro culture might somehow favour the detection of
donor-derived LCs. However, there is no a priori reason to justify
this, and early after transplantation, it is possible to recover high
numbers of recipient LCs by migration.
No technique is perfect, and in situ methods are liable to over-
estimate the proportion of recipient LC nuclei because the intri-
cate branching of LC membrane can lead to the inadvertent
inclusion of recipient keratinocyte nuclei. This problem may be
minimized using the more intense peri-nuclear distribution of
Langerin to detect LC nuclei; Langerin also has the distinct advan-
tage of protease resistance that permits immunofluorescence to be
performed after FISH. In addition, Z-stack reconstructions ensure
that scored nuclei are completely encapsulated in LC membrane,
and post-GVHD skin may be used to provide controls in which a
very high proportion of donor LCs is expected. Using these
approaches, high donor LC engraftment was also recently observed
in a study incorporating a large cohort of minimally conditioned
patients (13).
These considerations aside, Andani and colleagues have analy-
sed a homogenous population of patients without GVHD, and
their conclusion is that there is significant persistence of recipient
LCs in the absence of skin inflammation. This is certainly in keep-
ing with the reports of human limb transplantation, in which
donor LCs survive long-term (14), and highlights the many clini-
cal variables that must be accommodated when interpreting
human studies. A critical factor is the definition of GVHD,
because subclinical skin inflammation may promote donor LC
engraftment (13). Previous reports would suggest that without
GVHD, day 100 LC engraftment has a median of 90–95%,
although the outliers of these studies overlap with the new data
and are unlikely to be statistically separable (7,8,13).
The role of LCs in murine transplantation models is still
debated. While it is clear that LCs may trigger acute GVHD if
they are the only recipient APCs remaining (5,15), they may be
deleted without consequence in other models (16). In a third sce-
nario of mixed chimerism, LCs play a critical local role in epider-
mal inflammation (17). A recent trial of UV light treatment
during human transplantation concluded that a lower risk of
GVHD was associated with a reduction in LC numbers (18).
Humans with GATA2 mutation lacking DCs but retaining LCs
and macrophages also still experience GVHD (19–21).
A new facet of GVHD research is the potential of stable recipi-
ent macrophages to promote GVHD. In human transplantation,
macrophages outlive LCs and can stimulate allogeneic memory
T-cell responses in vitro (22). In mice, it has now been formally
demonstrated that tissue macrophages, like LCs, may also be main-
tained without bone marrow-derived precursors, leaving many
models of GVHD pathogenesis open to reinterpretation (23–25).
In conclusion, we know that many recipient LCs are intact at
the moment that donor T cells are infused into humans, and it
remains difficult to rule out a contribution of recipient LC-medi-
ated antigen presentation to acute GVHD. However, despite the
persistence of many investigators, it remains increasingly hard to
envisage that measurements of post-transplant LC chimerism will
lead to useful clinical decisions.
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